• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Charting New Paths: Mannatech Expanding with Thailand Office, Grand Opening, September 2024

    4/24/24 5:00:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email

    Mannatech, Incorporated (NASDAQ:MTEX), a leading global health and wellness company committed to transforming lives through Glycan technology, is thrilled to announce a significant milestone in its expansion efforts. With a steadfast commitment to empowering individuals and communities through innovative health solutions, Mannatech is excited to announce its continued expansion into the ASEAN region, with the official launch into the Thailand market.

    This opening will bring Mannatech's global presence to 26 markets. ^

    Existing and future Mannatech Associates eagerly anticipate the official launch in Thailand on June 17, 2024. During the soft opening, individuals will be able to register as Mannatech Associates. Additionally, we will launch Luminovation™ skin care, our premier K-Beauty line. This marks the initial step towards establishing a robust presence in the region, laying the groundwork for the future. This new market launch signifies a momentous occasion for Mannatech and its dedicated Associates.

    "Mannatech's expansion into Thailand is our first new market in several years and provides an exciting opportunity to introduce our products to a new country and culture. The opening team, led by Roh Jae-hong, Mannatech Korea's general manager, has conducted extensive market research, and worked tirelessly to prepare for this launch. We are confident that our products and business model are well suited for the Thailand market," said Landen Fredrick, President and CEO.

    Thailand is regarded as a market with high potential, with a population of 70 million, a direct sales market of about USD $3.1 billion and dietary supplement market of USD $3.9 billion in 2020. Mannatech's entry into Thailand is expected to serve as the bridgehead for pioneering the Southeast Asian market.

    "Interest in this market has been high, and I believe in the team's ability to develop and grow this market. The team looks forward to supporting our new customers and Associates and introducing them to our flagship Glycan technology," added Roh Jae-hong, Mannatech Korea General Manager.

    Designed to foster collaboration, innovation, and growth, the New Thailand office embodies Mannatech's unwavering commitment to providing unparalleled support to its independent sales Associates. From hosting meetings to conducting training sessions, the facility is primed to facilitate the success of Mannatech Associates as they embark on their entrepreneurial journeys.

    Thailand office address; No. 90 Ratchadaphisek Road, Huai Khwang Sub-district, Huai Khwang District, Bangkok, 10310, Thailand

    Mannatech Thailand will hold a grand opening event in September 2024.

    Mannatech's Thailand office grand opening will have a number of special guests including the company's President and CEO, Landen Fredrick, Mannatech Korea's General Manager, Roh Jae-Hong, and other Mannatech dignitaries.

    Mannatech Associates around the world are welcome to attend as well as interested members of the public.

    Stay tuned for further updates as Mannatech paves the way for a brighter, healthier future in Thailand and beyond.

    To begin transforming your life or the lives of those around you, please visit Mannatech.com.

    About Mannatech

    The world leader in Glycan technology, Mannatech is revolutionizing nutrition, immune health, fat loss, skin care and more. It is Mannatech's mission to help people live happier, healthier, enriched lives by developing scientifically sound, innovative wellness solutions and fostering a culture where the entrepreneurial spirit thrives. With more than 30 years of experience and operations in more than 25 countries, Mannatech is committed to transforming lives.

    For more information, visit Mannatech.com.

    ^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

    Please note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "intend" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain Associates and Members, increases in competition, litigation, regulatory changes and its planned growth into new international markets. Although Mannatech believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240424460689/en/

    Get the next $MTEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    9/10/24 5:45:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jobe Larry A was granted 4,790 shares, increasing direct ownership by 8% to 62,197 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:37:56 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Robbins Kevin Andrew was granted 4,790 shares, increasing direct ownership by 22% to 26,233 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:36:47 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Director John Seifrick A was granted 4,790 shares, increasing direct ownership by 53% to 13,746 units (SEC Form 4)

    4 - MANNATECH INC (0001056358) (Issuer)

    1/6/26 2:35:41 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Promotion of Peter Griscom to Chief Operating Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announces the promotion of Peter Griscom to Chief Operating Officer of Mannatech Incorporated (the "Company") effective July 1, 2025. Peter Griscom brings more than 10 years of experience in the direct selling channel and has extensive experience in working in the consumer goods space, including launching, leading, and restructuring companies while creating efficiencies in manufacturing, sales, and marketing. Prior to his promotion, Mr. Griscom served as the Company's senior vice president of global operations since August 21, 2024 and prior to that served as the senior vice president of product, innovation, & supply chain from July 3, 2023 through A

    6/26/25 2:11:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    SEC Filings

    View All

    Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    11/12/25 4:05:07 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Mannatech Incorporated

    10-Q - MANNATECH INC (0001056358) (Filer)

    11/12/25 4:03:53 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Incorporated filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - MANNATECH INC (0001056358) (Filer)

    9/12/25 4:22:20 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    View All

    Mannatech Announces Results of Annual Shareholders' Meeting

    Mannatech, Incorporated (Nasdaq: MTEX) ("Mannatech"), a global health and wellness company committed to transforming lives to make a better world, announced that its shareholders passed all proposals put to a vote at Mannatech's annual shareholder meeting (the "Meeting") held Tuesday, June 3, 2025. Mannatech's Chairman of the Board, J. Stanley Fredrick, chaired the Meeting, and James Clavijo, Mannatech's Chief Financial Officer, spoke to the shareholders sharing the company's financial results for 2024. There were 1,900,930 outstanding shares of Mannatech's common stock as of April 8, 2025 entitled to vote and 1,478,342 shares, or approximately 77.8% represented at the Meeting, either i

    6/5/25 2:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

    Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

    11/26/24 4:30:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

    Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

    7/1/24 5:46:00 PM ET
    $AEZS
    $MTEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $MTEX
    Financials

    Live finance-specific insights

    View All

    Mannatech Reports Financial Results for Third Quarter 2025

    FLOWER MOUND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2025. Third Quarter Results Net sales for the quarter ended September 30, 2025 were $29.2 million, as compared to $31.7 million for the same period in 2024, a decrease of $2.6 million, or 8.1%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $2.3 million, or 7.3%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. Th

    11/12/25 4:02:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for Second Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2025. Second Quarter Results Net sales for the quarter ended June 30, 2025 were $25.7 million, as compared to $27.7 million for the same period in 2024, a decrease of $2.1 million, or 7.4%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.8 million, or 6.5%, and unfavorable foreign exchange caused a $0.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    8/12/25 5:18:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    Mannatech Reports Financial Results for First Quarter 2025

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

    5/13/25 6:06:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Mannatech Incorporated

    SC 13G - MANNATECH INC (0001056358) (Subject)

    11/1/24 11:44:29 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    1/13/23 11:03:46 AM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

    SC 13G/A - MANNATECH INC (0001056358) (Subject)

    2/7/22 6:32:28 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care